Long-term follow-up (median 5.6 years) of a phase II/III trial in 261 patients with postoperative high-risk head and neck squamous cell cancer: weekly cisplatin chemoradiotherapy remained non-inferior to 3-weekly; 5-year OS 71.2% vs 58.7% (HR 0.76).
Clinical trialn = 261
Tahara et al. Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer